You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


A.C.T. N.O.W. A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer's Disease

  • Authors: Marwan Sabbagh, MD, FAAN; R. Scott Turner, MD, PhD
  • CME Released: 3/28/2018
  • Valid for credit through: 3/28/2019, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists and other healthcare professionals who manage patients with Alzheimer's disease.

The majority of those with Alzheimer’s disease (AD) experience significant delays in diagnoses; it can be years before patients are referred to neurologists for a proper diagnosis. Further complicating matters after diagnosis, the care of AD patients is often fragmented, uncoordinated, and unresponsive to patients’ needs and those of their caregivers and families.

Significant time and skill are required to accurately diagnose neurologic conditions, communicate a life-shattering diagnosis to patients, and discuss and manage treatment options. Neurologists play a definitive role in the management of AD patients, and this CME-certified activity is designed to help these clinicians stay up to date with cutting-edge science on the early recognition of cognitive impairment, explore new tools and techniques to confirm diagnoses, and recognize where traditional and emerging therapies belong in the treatment armamentarium.

“A.C.T. N.O.W. - A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer’s Disease” will also address the following National Alzheimer’s Project Act priorities: 1) accelerate the development of treatments that would prevent, halt, or reverse the course of AD; and 2) improve early diagnosis and coordination of care and treatment of AD.

Upon completion of this activity, participants will be able to:

  1. Describe the critical importance of early recognition of mild cognitive impairment and early cognitive decline
  2. Outline the mechanism of action, clinical endpoints, and efficacy and safety of current and emerging treatment options for AD, their places in the current and evolving treatment paradigms, and strategies for becoming engaged in clinical trials
  3. Describe the success of neurologist-led initiatives to establish multidisciplinary collaborative care models for AD and action-based steps and resources for implementation of similar programs


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


  • Marwan Sabbagh, MD, FAAN

    Karsten Solheim Chair for Dementia, Professor of Neurology, Director, Alzheimer’s and Memory Disorders Division, Barrow Neurological Institute, Research Professor of Neurology, UA College of Medicine-Phoenix, Phoenix, Arizona


    Disclosure: Consultant: Axovant Sciences, Biogen, Grifols, Lilly Pharmaceuticals, Sanofi, vTv Therapeutics; Research: Avid Pharmaceuticals, Axovant Sciences, Biogen, Genentech, Lilly Pharmaceuticals, Merck, Pfizer, Roche Diagnostics Corporation, Suven Life Sciences, vTv Therapeutics; Stock/Shareholder: Brain Health, Muses Labs, OCHC, Versanum; Royalties: Harper Collins.

  • R. Scott Turner, MD, PhD

    Professor of Neurology, Director, Memory Disorders Program, Georgetown University Medical Center, Washington, DC


    Disclosure: Grant/Research Support: Acadia, Biogen, Lilly, Merck, Novartis.

Additional Planners/Reviewers

Chad Williamson, MS, MBA, CMPP; Blair St. Amand; Lindsay Scott, PT, DPT, ATC: Nothing to disclose.

Accreditation Statements

    For Physicians

  • Rockpointe

    Jointly provided by the Potomac Center for Medical Education and Rockpointe.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

    The Potomac Center for Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


A.C.T. N.O.W. A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer's Disease

Authors: Marwan Sabbagh, MD, FAAN; R. Scott Turner, MD, PhDFaculty and Disclosures

CME Released: 3/28/2018

Valid for credit through: 3/28/2019, 11:59 PM EST


Before you begin, please answer the questions in this brief questionnaire.

  • Print